Rapport Therapeutics (RAPP) Preferred Stock Liabilities (2023 - 2024)
Rapport Therapeutics' (RAPP) quarterly Preferred Stock Liabilities came in at $145.3 million in Q1 2024, down 12.8% on a QoQ basis from $166.6 million in Q4 2023.
Rapport Therapeutics (RAPP) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Rapport Therapeutics (RAPP) has 2 years of Preferred Stock Liabilities data on file, last reported at $145.3 million in Q1 2024.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $145.3 million in Q1 2024; TTM through Mar 2024 was $145.3 million, a N/A change from a year earlier, with the FY2023 full-year figure at $166.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2024 stood at $145.3 million, down from $166.6 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for RAPP reached as high as $166.6 million in Q4 2023 and fell as low as $89.5 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Rapport Therapeutics | 1.95 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 145.25 Mn |
| Dec 31, 2023 | 166.58 Mn |
| Sep 30, 2023 | 89.49 Mn |
| Jun 30, 2023 | 89.49 Mn |